2216 — Broncus Holding Share Price
- HK$1.29bn
- HK$210.75m
- $8.13m
- 27
- 14
- 80
- 33
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.98 | ||
Price to Tang. Book | 1.03 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 20.41 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -8.98% | ||
Return on Equity | -8.63% | ||
Operating Margin | -187.14% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 3.26 | 10.89 | 9.41 | 10.26 | 8.13 | 11.82 | 16.97 | 0.15% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Broncus Holding Corp is an investment holding company providing innovative solutions for lung diseases. The Company's business includes providing diagnostic solutions, lung cancer treatment solutions, chronic obstructive pulmonary disease solutions and navigation platforms. The diagnostic solutions pruducts include FleXNeedle, ATV Sheath, ATV Balloon and others. The lung cancer treatment solutions products include InterVapor for lung cancer, H-Marker and others. The chronic obstructive pulmonary disease (COPD) solutions products include InterVapor for COPD and TLD Ablation System. The navigation platform products include Lungpoint, Lungpro, New Generation Navigation Platform and others.
Directors
- Yiwei Zhao NEC (55)
- Guowei Zhan CEO (45)
- Todd Cornell CEX (51)
- Hong Xu CTO (35)
- Zhenhua Li DSL (37)
- Jeanie Lau SEC (44)
- Wen Hao Wang SEC (48)
- Ao Zhang NED (36)
- Zhenjun Zi NED (51)
- Jian Ji NID (51)
- Pok Man Kam NID (71)
- Wan Yee Lau NID (74)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 30th, 2012
- Public Since
- September 24th, 2021
- No. of Employees
- 200
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited
- Shares in Issue
- 525,540,076

- Address
- Room 801, 8/F, Building 8, HANGZHOU
- Web
- https://www.broncus.com/
- Phone
- Auditors
- Ernst & Young Australia
Upcoming Events for 2216
Similar to 2216
Acotec Scientific Holdings
Stock Exchange of Hong Kong Limited
Beijing Airdoc Technology Co
Stock Exchange of Hong Kong Limited
AK Medical Holdings
Stock Exchange of Hong Kong Limited
AMCO United Holding
Stock Exchange of Hong Kong Limited
Angelalign Technology
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:42 UTC, shares in Broncus Holding are trading at HK$2.45. This share price information is delayed by 15 minutes.
Shares in Broncus Holding last closed at HK$2.45 and the price had moved by +380.39% over the past 365 days. In terms of relative price strength the Broncus Holding share price has outperformed the FTSE Developed Asia Pacific Index by +385.88% over the past year.
The overall consensus recommendation for Broncus Holding is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBroncus Holding does not currently pay a dividend.
Broncus Holding does not currently pay a dividend.
Broncus Holding does not currently pay a dividend.
To buy shares in Broncus Holding you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$2.45, shares in Broncus Holding had a market capitalisation of HK$1.29bn.
Here are the trading details for Broncus Holding:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2216
Based on an overall assessment of its quality, value and momentum Broncus Holding is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Broncus Holding is HK$1.55. That is 36.62% below the last closing price of HK$2.45.
Analysts covering Broncus Holding currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Broncus Holding. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +419.22%.
As of the last closing price of HK$2.45, shares in Broncus Holding were trading +284.37% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Broncus Holding PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$2.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Broncus Holding's management team is headed by:
- Yiwei Zhao - NEC
- Guowei Zhan - CEO
- Todd Cornell - CEX
- Hong Xu - CTO
- Zhenhua Li - DSL
- Jeanie Lau - SEC
- Wen Hao Wang - SEC
- Ao Zhang - NED
- Zhenjun Zi - NED
- Jian Ji - NID
- Pok Man Kam - NID
- Wan Yee Lau - NID